Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)
Completed
Phase 4 ResultsSummary of Purpose
The KYOTO HEART Study is to assess the add-on effect of valsartan, an Angiotensin-Receptor Blocker, on top of the conventional treatment in high risk patients in Japan with hypertension in terms of the morbidity and mortality.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 9 December 2012.
| 1 Jan 2004 | 6 Sep 2005 | 1 Jan 2009 | 1 Jan 2009 | 1 Dec 2012 | 5 Jul 2011 |
| Start Date | First Received | 1st Completion | Completion | Verification | Results |
|---|
Trial Design
- Allocation: Randomized
- Masking: Open Label
- Purpose: Diagnostic
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
Not available
View Trial Locations
Recruitment
- Enrollment: 3,031
- Gender: Both
- Minimum Age: 20 Years
- Accepts Healthy Volunteers: No
- 1 location, 1 country
Principal Investigator
- Hiroaki Matsubara, MD,PhD
Kyoto Prefectural University of Medicine
